全文获取类型
收费全文 | 38261篇 |
免费 | 2771篇 |
国内免费 | 211篇 |
专业分类
耳鼻咽喉 | 503篇 |
儿科学 | 1254篇 |
妇产科学 | 1004篇 |
基础医学 | 4233篇 |
口腔科学 | 1082篇 |
临床医学 | 3042篇 |
内科学 | 8365篇 |
皮肤病学 | 1059篇 |
神经病学 | 1981篇 |
特种医学 | 1343篇 |
外国民族医学 | 14篇 |
外科学 | 6703篇 |
综合类 | 840篇 |
现状与发展 | 1篇 |
一般理论 | 23篇 |
预防医学 | 2722篇 |
眼科学 | 1077篇 |
药学 | 3236篇 |
中国医学 | 237篇 |
肿瘤学 | 2524篇 |
出版年
2023年 | 443篇 |
2022年 | 1343篇 |
2021年 | 1917篇 |
2020年 | 1088篇 |
2019年 | 1507篇 |
2018年 | 1971篇 |
2017年 | 1258篇 |
2016年 | 1327篇 |
2015年 | 1347篇 |
2014年 | 1761篇 |
2013年 | 2253篇 |
2012年 | 2900篇 |
2011年 | 3031篇 |
2010年 | 1728篇 |
2009年 | 1489篇 |
2008年 | 1932篇 |
2007年 | 1989篇 |
2006年 | 1783篇 |
2005年 | 1521篇 |
2004年 | 1436篇 |
2003年 | 1120篇 |
2002年 | 1054篇 |
2001年 | 617篇 |
2000年 | 628篇 |
1999年 | 513篇 |
1998年 | 242篇 |
1997年 | 182篇 |
1996年 | 160篇 |
1995年 | 142篇 |
1994年 | 107篇 |
1993年 | 88篇 |
1992年 | 163篇 |
1991年 | 154篇 |
1990年 | 138篇 |
1989年 | 129篇 |
1988年 | 123篇 |
1987年 | 116篇 |
1986年 | 109篇 |
1985年 | 111篇 |
1984年 | 148篇 |
1983年 | 152篇 |
1982年 | 77篇 |
1981年 | 70篇 |
1980年 | 69篇 |
1979年 | 122篇 |
1978年 | 87篇 |
1977年 | 83篇 |
1976年 | 75篇 |
1975年 | 78篇 |
1974年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Ahmed M. Abu El-Asrar Ajmal Ahmad Eef Allegaert Mohammad Mairaj Siddiquei Priscilla W. Gikandi Gert De Hertogh 《Ocular immunology and inflammation》2020,28(4):575-588
ABSTRACT
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献2.
3.
4.
Huda Mohammed Alkreathy Mayson H. Alkhatib Safaa Ahmed Al Musaddi Khadijah Saeed A. Balamash Nadia Nour Osman Aftab Ahmad 《Clinical and experimental pharmacology & physiology》2019,46(5):496-505
Doxorubicin (DOX) is the most commonly used anticancer drug; however, it has limited use because prolonged administration may result in severe cardiotoxicity. Simvastatin (SIM), generally prescribed for hypercholesterolaemia, has also shown salubrious results in the monotherapy or combinational drug therapy of different cancers in various models. Nanoparticle drug delivery systems are a novel way of improving therapeutics and also improving the absorption and specificity of drugs towards tumour cells. In this study, we exploited this technology to increase drug specificity and minimize imminent adverse effects. In this study, the antitumour activity of the combination formulas of DOX and SIM, either loaded in water (DOX‐SIM‐Solution) or nanoemulsions (NEs) (DOX‐SIM‐NE), was evaluated in a Swiss albino mouse model of Ehrlich ascites carcinoma. The anticancer effect was assessed by quantifying the change in body weight, mean survival time, and percent increase in lifespan (%ILS), determining haematological and serum biochemical parameters (liver function test, kidney function test and lipid profile parameters) as well as studying the histopathological alterations in liver tissues. We observed a clear increase in %ILS of the DOX‐SIM‐Solution group (265.30) that was double the %ILS of the DOX‐SIM‐NE group (134.70). However, DOX‐SIM‐NE had a non‐toxic effect on the haematological parameters, whereas DOX‐SIM‐Solution increased the levels of haemoglobin and lymphocytes. Furthermore, the encapsulation of SIM and DOX into NEs improved the levels of all serum biochemical parameters compared to the DOX‐SIM‐Solution. A reduction in the side effects of DOX‐SIM‐NE on the liver was also established using light microscopy, which revealed that the morphologies of the hepatocytes of the mice were less affected by administration of the DOX‐SIM‐NE treatment than with the DOX‐SIM‐Solution treatment. The study showed that incorporating SIM into the DOX‐loaded‐NE formulation remarkably improved its efficiency and simultaneously reduced its adverse effects. 相似文献
5.
Objectives
Iatrogenic injury of the Profunda Femoris Artery (PFA) at time of hip fixation surgery can increase morbidity and mortality and prolong the hospital stay. This is an injury that tends to pass unnoticed as a cause of postoperative deterioration despite being frequently reported in the literature. Our study aims to describe the anatomy of the PFA in relation to the medial femoral cortex with specific emphasis on its orientation relative to the position of a sliding hip screw side plate construct. By doing so we are able to present clear guidance to orthopaedic surgeons on how to avoid iatrogenic PFA injury at the time of hip fracture fixation.Methods
Using Computed Tomography Angiographic (CTA) studies, the course of the PFA in relation to the medial femoral cortex was traced in 44 patients (28 males and 16 females) with mean age of 65.6 years. Coronal and axial CT sections were cross-linked to specify the position of the PFA at 1?cm intervals.Results
The course of the artery could be divided into three parts relative to a fixed reference point. Proximal and distal parts of the artery were in a safer position in comparison to the middle part of the artery that was found very close to the femoral cortex and along the coronal axis of the femur (mean angle 2.9° from the femoral coronal axis and 13.8?mm from the medial femoral cortex). Using the commercially available side plate constructs, this part of the artery corresponded to the distal part of the plate (third and fourth holes).Conclusion
Special attention needs to be practiced by the operating surgeon while drilling into the third and fourth holes of the side plate. 相似文献6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
8.
9.
Letter: faecal volatile organic metabolites,promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors’ reply 下载免费PDF全文
I. Ahmed R. Greenwood B. Costello N. Ratcliffe C. Probert 《Alimentary pharmacology & therapeutics》2016,43(11):1241-1242
10.